Laboratorios Saval S.A. has acquired a pharmeceutical processing plant
January 2023 — Laboratorios Saval S.A. has acquired a pharmeceutical processing plant in Costa Rica from Laboratorios Stein S.A.
Laboratorios Saval is a Chilean company with more than 80 years of history. It began its history in Spain in the 1930s and today, has a presence in more than 14 countries. The company manufactures and distributes pharmaceuticals in the areas of infectious diseases, ophthalmology, immunology and oncology, gastroenterology, bronchopulmonary, cardiology, psychiatry and rheumatology.
Laboratorios Stein is a leading company in Latin America in the commercialization and distribution of highly complex pharmaceutical products including innovative products, biosimilars and complex generics.
Our role in the transaction
Oaklins’ team in Chile acted as financial advisor to Laboratorios Saval in this transaction.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreBischoff & Bischoff has acquired Trendmobil
Bischoff & Bischoff Medizin- und Rehabilitationstechnik GmbH, a portfolio company of Lafayette Mittelstand Capital, has acquired Trendmobil GmbH as a strategic add-on.
Learn moreClinic DPC has been acquired by Meliva
Meliva has acquired 100% of Lithuanian dental care provider Clinic DPC from United Clinics. The transaction further strengthens Meliva’s dental care offering and represents another step in its strategy to expand its presence in the Lithuanian private healthcare market.
Learn more